(Q45879674)

17 December 2017

title

Acquired hemophilia in malignancy (English)

1 reference

17 December 2017

0 references

1 reference

Brandi N Reeves

1

1 reference

17 December 2017

Nigel S Key

series ordinal

2

1 reference

17 December 2017

publication date

1 April 2012

1 reference

17 December 2017

published in

Thrombosis Research

1 reference

17 December 2017

volume

129 Suppl 1

1 reference

17 December 2017

page(s)

S66-8

1 reference

17 December 2017

CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Proceedings: Causes of death in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

1 reference

7 January 2021

Laboratory, clinical and therapeutic aspects of acquired hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Acquired inhibitors in malignant and nonmalignant disease states

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Pathophysiology of acquired von Willebrand disease: a concise review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970019-1

7 January 2021

10.1016/S0049-3848(12)70019-1

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

22682137

1 reference

17 December 2017